PG-545 is a heparan sulfate (HS) mimetic that inhibits tumour angiogenesis by sequestering angiogenic growth factors in the extracellular matrix (ECM), thus limiting subsequent binding to receptors. Importantly, PG-545 also inhibits heparanase, the only endoglycosidase which cleaves HS chains in the ECM. The anti- respiratory syncytial virus (RSV) activity of PG-545 was due to both partial inhibition of the virus attachment to cells and a more profound interference with some post-attachment steps as PG-545 efficiently neutralized infectivity of the cell-adsorbed virus. The anti-RSV activity of PG-545 was reduced when tested in the presence of human nasal secretions. Serial passages of RSV in the presence of increasing concentrations of PG-545 selected for weakly resistant viral variants that comprised the F168S and the P180S amino acid substitutions in the viral G protein. PG-545 has an immunomodulatory properties. PG-545 stimulates innate immune responses against tumours in preclinical cancer models. PG-545 is in phase I clinical trial for the treatment of pancreatic cancer.

Olpimedone was developed as an anti-rheumatic agent and analgesic, however, the drug that has never been marketed. Information about the current use of olpimedone is not available.

Olpimedone was developed as an anti-rheumatic agent and analgesic, however, the drug that has never been marketed. Information about the current use of olpimedone is not available.

Olpimedone was developed as an anti-rheumatic agent and analgesic, however, the drug that has never been marketed. Information about the current use of olpimedone is not available.

Olpimedone was developed as an anti-rheumatic agent and analgesic, however, the drug that has never been marketed. Information about the current use of olpimedone is not available.

Olpimedone was developed as an anti-rheumatic agent and analgesic, however, the drug that has never been marketed. Information about the current use of olpimedone is not available.

(+)-Fadrozole (FAD-286) is an aldosterone synthase inhibitor. The drug was tested in vivo in preclinical models of hypertension, heart failure and was shown to reduce retinal neovascularization in rats with oxygen-induced retinopathy.